Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01568879 · ClinicalTrials.gov registry record · NA

Evaluating the Effectiveness of a Chronic Disease Management Program for Gout

A NA study of Recurrent or Tophaceous Gout, sponsored by Kaiser Permanente.

Completed
Registry status
NA
Development phase
104
Enrollment target
1
Study location

NCT01568879: Completed NA study of Recurrent or Tophaceous Gout, sponsored by Kaiser Permanente.

NCT01568879 is a NA study of Recurrent or Tophaceous Gout that has completed, run by Kaiser Permanente. The registered enrollment target is 104 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01568879, a NA study of Recurrent or Tophaceous Gout, has completed, sponsored by Kaiser Permanente.

COMPLETED
Registry status
NA
Development phase
104 participants
Enrollment target
1
Study location

Study Summary

The aim of this study is to test the effectiveness of a pharmacist-staffed, protocol-based chronic disease management program compared to patients receiving usual care in achieving a target serum uric acid level in patients with recurrent gout.

Primary Outcome

attainment and maintenance of a serum uric acid level of 6.0 mg/dl or less. The outcome will be considered positive if that level is attained and the 6 month follow up value remains at the target level.

Interventions

  • OTHER Control
  • OTHER Gout Disease Management Program

Study Locations (1)

California

  • Kaiser Permanente Northern California Medical Facilities - All KPNC Facilities

Trial Details

FieldValue
Enrollment Target 104 participants
Start Date 2012-01
Est. Completion 2014-11
Phase NA
Kaiser Permanente

294 total trials

What the finished NCT01568879 record still lists

NCT01568879 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Recurrent or Tophaceous Gout appearing as the primary indexed condition, and to 2 interventions - of which Control is the first listed.

NCT01568879 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT01568879 about?

NCT01568879 is a clinical study titled "Evaluating the Effectiveness of a Chronic Disease Management Program for Gout". The aim of this study is to test the effectiveness of a pharmacist-staffed, protocol-based chronic disease management program compared to patients receiving usual care in achieving a target serum uric acid level in patients with recurrent gout.

What is the current status of trial NCT01568879?

This trial is currently completed. It is a NA study. The enrollment target is 104 participants. The study started on 2012-01. Estimated completion is 2014-11.

What conditions does trial NCT01568879 study?

This clinical trial studies the following conditions: Recurrent or Tophaceous Gout.

What interventions are being tested in trial NCT01568879?

The interventions under investigation include: Control (OTHER), Gout Disease Management Program (OTHER).

Who is sponsoring clinical trial NCT01568879?

This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01568879 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT01568879's enrollment target sits among peer trials

104 836th of 2000 higher than 1,164 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03403686 · 104 participants

    Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

  • NCT04228367 · 104 participants · NA

    JuggerStitch Post Market Clinical Follow-up Study

  • NCT04268849 · 104 participants · Phase 3

    Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

  • NCT04390724 · 104 participants

    Optimizing Y90 Therapy for Radiation Lobectomy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01568879, the US trial registry maintained by the National Library of Medicine. NCT01568879 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.